Nonclinical toxicology assessments support the chronic safety of dapagliflozin, a first-in-class sodium-glucose cotransporter 2 inhibitor

International Journal of Toxicology

Volumn 32, Issue 5, 2013, Pages 336-350

  Tirmenstein, Mark ^a   Dorr, Thomas E ^a   Janovitz, Evan B ^a   Hagan, Deborah ^a   Abell, Lynn M ^a   Onorato, Joelle M ^a   Whaley, Jean M ^a   Graziano, Michael J ^a   Reilly, Timothy P ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

bone; dapagliflozin; glucosuria; pharmaceutical safety; SGLT2 inhibition; type 2 diabetes

Indexed keywords

DAPAGLIFLOZIN; DAPAGLIFLOZIN 3 O GLUCURONIDE; DRUG METABOLITE; SODIUM GLUCOSE COTRANSPORTER 2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BONE DEMINERALIZATION; CALCIUM ABSORPTION; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG SCREENING; DRUG SELECTIVITY; FEMALE; GLUCOSURIA; IN VITRO STUDY; KIDNEY; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; OSMOTIC DIURESIS; RAT; SINGLE DRUG DOSE; SPRAGUE DAWLEY RAT; TOXICOKINETICS; UROGENITAL SYSTEM;

BONE; DAPAGLIFLOZIN; GLUCOSURIA; PHARMACEUTICAL SAFETY; SGLT2 INHIBITION; TYPE 2 DIABETES;

ANIMALS; CHO CELLS; CRICETULUS; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; FEMALE; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MICE; MICE, INBRED ICR; MICE, KNOCKOUT; RATS; RATS, SPRAGUE-DAWLEY; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84887844360     PISSN: 10915818     EISSN: 1092874X     Source Type: Journal    
DOI: 10.1177/1091581813505331     Document Type: Article

References (36)

1. World Health Organization. Diabetes. World Health Organization Web site.http://www.who.int/mediacentre/factsheets/fs312/en/. Accessed March 12, 2013.
2. Cheung BM, Ong KL, Cherny SS, Sham PC, Tso AW, Lam KS. Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006. Am J Med. 2009 ; 122 (5). 443-453
3. Dodd AH, Colby MS, Boye KS, Fahlman C, Kim S, Briefel RR. Treatment approach and HbA1c control among US adults with type 2 diabetes: NHANES 1999-2004. Curr Med Res Opin. 2009 ; 25 (7). 1605-1613
4. Chao EC, Henry RR. SGLT2 inhibition - a novel strategy for diabetes treatment. Nat Rev Drug Discov. 2010 ; 9 (7). 551-559
5. Whaley JM, Tirmenstein M, Reilly TP, et al. Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus. Diabetes Metab Syndr Obes. 2012 ; 5: 135-148
6. Washburn WN, Poucher SM. Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus. Expert Opin Investig Drugs. 2013 ; 22 (4). 463-486
7. Chen J, William S, Ho S, et al. Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members. Diabetes Ther. 2010 ; 1 (2). 57-92
8. You G, Lee WS, Barros EJ, et al. Molecular characteristics of Na(+)-coupled glucose transporters in adult and embryonic rat kidney. J Biol Chem. 1995 ; 270 (49). 29365-29371
9. Wright EM, Hirayama BA, Loo DF. Active sugar transport in health and disease. J Intern Med. 2007 ; 261 (1). 32-43
10. Bays H. From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus. Curr Med Res Opin. 2009 ; 25 (3). 671-681
11. Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR. Risk factors for renal dysfunction in type 2 diabetes: UK Prospective Diabetes Study 74. Diabetes. 2006 ; 55 (6). 1832-1839
12. Han S, Hagan DL, Taylor JR, et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes. 2008 ; 57 (6). 1723-1729
13. Onorato JM, Langish RA, Shipkova PA, et al. A novel method for the determination of 1,5-anhydroglucitol, a glycemic marker, in human urine utilizing hydrophilic interaction liquid chromatography/MS(3). J Chromatogr B Analyt Technol Biomed Life Sci. 2008 ; 873 (2). 144-150
14. Vallon V, Platt KA, Cunard R, et al. SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol. 2011 ; 22 (1). 104-112
15. Poucher SM, DeSchoolmeester JL, Ehnebom J, Vernon W, Clementz T. Dapagliflozin selectivity for glucose transporters GLUT 1, 2 and 4 [abstract]. Diabetes. 2011 ; 60 (suppl 1). 1041 - P
16. Gopinath G, Prentice DE, Lewis DJ Atlas of Experimental Toxicologic Pathology (Current Histopathology, V. 13). Gopinath C Prentice DE Lewis DJ, ed. Boston, MA: MTP Press Limited ; 1987: 104-121.
17. Greaves P Histopathology of Preclinical Toxicity Studies. 3 rd ed. New York, NY: Academic Press; 2007:809-811. New York, NY: Academic Press ; 2007: 809-811.
18. Paul SM, Mytelka DS, Dunwiddie CT, et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov. 2010 ; 9 (3). 203-214
19. Lang F. Osmotic diuresis. Ren Physiol. 1987 ; 10 (3-4). 160-173
20. Stanton BA. Regulation of Na+ and K+ transport by mineralocorticoids. Semin Nephrol. 1987 ; 7 (1). 82-90
21. Jurczak MJ, Lee HY, Birkenfeld AL, et al. SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function. Diabetes. 2011 ; 60 (3). 890-898
22. Baylis C, Corman B. The aging kidney: insights from experimental studies. J Am Soc Nephrol. 1998 ; 9 (4). 699-709
23. Til HP, Kuper CF, Falke HE, Bar A. Subchronic oral toxicity studies with erythritol in mice and rats. Regul Toxicol Pharmacol. 1996 ; 24 (2 pt 2). S221 - S231
24. Parikh S, Johnsson K, Ptaszynska A, Schmitz B, Sugg J, List JF. Characterization of urinary tract infections in the setting of pharmacologically induced glucosuria [abstract]. Diabetes. 2011 ; 60 (suppl 1). A270
25. Lantis AC, Atkins CE, DeFrancesco TC, Keene BW, Werre SR. Effects of furosemide and the combination of furosemide and the labeled dosage of pimobendan on the circulating renin-angiotensin-aldosterone system in clinically normal dogs. Am J Vet Res. 2011 ; 72 (12). 1646-1651
26. Horio Y, Tanaka T, Taketoshi M, Uno T, Wada H. Rat cytosolic aspartate aminotransferase: regulation of its mRNA and contribution to gluconeogenesis. J Biochem. 1988 ; 103 (5). 805-808
27. Zinker B, Ma X, Liu H, et al European Association for the Study of Diabetes; Berlin, Germany; 1-5 October 2012.
28. Kobayashi A, Yokoyama H, Kataoka J, et al. Effects of spaced feeding on gene expression of hepatic transaminase and gluconeogenic enzymes in rats. J Toxicol Sci. 2011 ; 36 (3). 325-337
29. Campbell JM, Fahey GC, Wolf BW. Selected indigestible oligosaccharides affect large bowel mass, cecal and fecal short-chain fatty acids, pH and microflora in rats. J Nutr. 1997 ; 127 (1). 130-136
30. Kasahara M, Maeda M, Hayashi S, Mori Y, Abe T. A missense mutation in the Na(+)/glucose cotransporter gene SGLT1 in a patient with congenital glucose-galactose malabsorption: normal trafficking but inactivation of the mutant protein. Biochim Biophys Acta. 2001 ; 1536 (2-3). 141-147
31. Wright EM. Genetic disorders of membrane transport. I. Glucose galactose malabsorption. Am J Physiol Gastrointest Liver Physiol. 1998 ; 275: G879 - G882
32. Zafar TA, Weaver CM, Zhao Y, Martin BR, Wastney ME. Nondigestible oligosaccharides increase calcium absorption and suppress bone resorption in ovariectomized rats. J Nutr. 2004 ; 134 (2). 399-402
33. Hard GC, Khan KN. A contemporary overview of chronic progressive nephropathy in the laboratory rat, and its significance for human risk assessment. Toxicol Pathol. 2004 ; 32 (2). 171-180
34. Nussey S, Whitehead S. Endocrinology: An Integrated Approach. Oxford, UK: BIOS Scientific Publishers ; 2001: 171-216.
35. FDA Briefing Document NDA 204042 Invokana (canagliflozin) Tablets. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM334550.pdf. Accessed March 20, 2013.
36. Zoetis T, Tassinari MS, Bagi C, Walthall K, Hurtt ME. Species comparison of postnatal bone growth and development. Birth Defects Res B Dev Reprod Toxicol. 2003 ; 68 (2). 86-110